What question did this study set out to answer?

This study aims to stratify locally advanced gastric cancer patients based on their potential to benefit from neoadjuvant therapy using tumor regression grade results.

May 27, 2026Open Access

Finding a predictive index for evaluating the efficacy of neoadjuvant therapy in locally advanced gastric cancer patients

Key Points

This study aims to stratify locally advanced gastric cancer patients based on their potential to benefit from neoadjuvant therapy using tumor regression grade results.
Retrospective analysis of 94 patients with locally advanced gastric adenocarcinoma who received neoadjuvant therapy from 2020 to 2023.
Multivariate analysis to assess associations between tumor regression grade and clinical factors, including tumor differentiation and N stage.
Development of the Clinical Predictive Pathological Remission Score (CPPRS) based on significant predictors.
The NICT group showed a higher tumor regression grade 0 rate compared to the NCT group (9/37 vs. 2/57, p = 0.004).
Significant associations were found between tumor regression grade and tumor differentiation (OR, 7.985; p = 0.007), N stage (OR, 13.286; p = 0.013), and tumor size (OR, 5.397; p = 0.030).
CPPRS demonstrated a strong correlation with tumor regression grade (p < 0.001).

Abstract

Abstract Background Emerging evidence suggests that the addition of immunotherapy may improve tumor regression grade (TRG) in locally advanced gastric cancer (LAGC) patients. However, the clinical benefit of immunotherapy in patients with low PD-1 expression remains a subject of debate and requires further exploration. Importantly, a proportion of Neoadjuvant immuno-chemotherapy group (NICT) patients did not present significant benefits from neoadjuvant therapy. The aim and objectives of our study is to stratify LAGC patients who can benefit from neoadjuvant therapy based on TRG results. Methods We conducted a retrospective study (2020–2023) included 94 LAGC patients (cT3N + M0, 4a-bNanyM0) with gastric adenocarcinoma who receiving neoadjuvant therapy (57 patients in the neoadjuvant chemotherapy (NCT) group, and 37 in NICT group). All patients received ulterior radical surgery, and clinicopathological data were retrospectively reviewed and analyzed. We introduced multivariate analysis demonstrated significant associations between TRG and Tumor differentiation (OR, 7.985; 95% CI, 0.998–34.370; p = 0.007), N stage (OR, 13.286; 95% CI, 1.861–50.324; p = 0.013), tumor size (OR, 5.397; 95% CI, 1.174–24.818; p = 0.030), and immunotherapy (OR, 16.872; 95% CI, 2.889–75.563; p 3.55 cm, and lymph node metastasis. Results NICT group exhibited a significantly higher TRG0 rate compared to the NCT group, independent of PD-1 expression (9/37 vs. 2/57, p = 0.004). Tumor differentiation (OR, 7.985; 95% CI, 0.998–34.370; p = 0.007), N stage (OR, 13.286; 95% CI, 1.861–50.324; p = 0.013), tumor size (OR, 5.397; 95% CI, 1.174–24.818; p = 0.030), and immunotherapy (OR, 16.872; 95% CI, 2.889–75.563; p < 0.001) were significantly associated with TRG. CPPRS demonstrated a strong correlation with TRG ( p < 0.001). Conclusions The addition of immunotherapy improves TRG in LAGC patients without the need for PD-1 expression assessment. CPPRS serves as a valuable predictive tool for evaluating the efficacy of neoadjuvant therapy in LAGC patients.

KI fragen

Bookmark

View Full Paper